Cannabidiol
Evidence-based neurology checklist on cannabidiol: Pharmacology Cannabidiol is an active component of the cannabis plant It does not have the eupohoria-inducing properties of tetrahydrocannabidiol It is metabolised by the cytochrome P450 enzyme system Co-administration with Clobazam has a…
Pharmacology
- Cannabidiol is an active component of the cannabis plant
- It does not have the eupohoria-inducing properties of tetrahydrocannabidiol
- It is metabolised by the cytochrome P450 enzyme system
- Co-administration with Clobazam has a beneficial effect
Potential mechanisms of action
Epilepsy indications: definite
Epilepsy indications: potential
Potential non-epilepsy indications for cannabinoids
Dose and use
Side effects
References
- Franco V, Perucca E. Pharmacological and therapeutic properties of cannabidiol for epilepsy. Drugs 2019; 79:1435-1454.
- Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Res 2019; pii: F1000 Faculty Rev-234.
- Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia 2019; 60:2224-2234.
- Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia 2019; 60:294-302.
- Dale T, Downs J, Olson H, Bergin AM, Smith S, Leonard H. Cannabis for refractory epilepsy in children: a review focusing on CDKL5 Deficiency Disorder. Epilepsy Res 2019; 151:31-39.
- And 8 more. Subscribe to see the full list
